Electronic Records and Signatures: Regulatory Expectations Across GxP Electronic Records and Signatures: Regulatory Expectations Across GxP In the evolving landscape of pharmaceutical and biotechnology industries, the reliance on digital systems for managing electronic records and signatures has become paramount. The integration of such systems must align with established regulations to maintain data integrity and ensure compliance. This article provides a comprehensive overview of the regulatory framework surrounding electronic records and signatures, focusing on relevant guidelines, documentation requirements, and common deficiencies in the context of regulatory affairs (RA). Context Regulatory Affairs professionals play a critical role in ensuring that digital systems…

Audit Trails in Practice: What Needs to Be Captured, Reviewed and Retained Audit Trails in Practice: What Needs to Be Captured, Reviewed and Retained Context The advent of digital systems has transformed the landscape of regulatory compliance in Pharma and Biotech. Audit trails are essential for ensuring data integrity, accountability, and traceability regarding electronic records and signatures. Compliance with 21 CFR Part 11 and EU Annex 11 requirements is a key regulatory expectation, necessitating a robust understanding of what should be captured, reviewed, and retained in audit trails. This article will guide you through the essential regulatory frameworks, agency expectations,…

Designing SOPs for Electronic Record Creation, Review and Approval Designing SOPs for Electronic Record Creation, Review and Approval In the evolving landscape of healthcare and pharmaceutical sectors, electronic records, signatures, and audit trails have become essential components of regulatory compliance for organizations. Ensuring adherence to the rigorous standards set forth by regulatory authorities such as the FDA, EMA, and MHRA is paramount for maintaining the integrity, reliability, and traceability of electronic records. This article serves as a comprehensive regulatory explainer manual, focusing on the requirements and best practices for designing Standard Operating Procedures (SOPs) for electronic record creation, review, and…

Linking Electronic Signatures to Identity, Training and Authorisation Matrices Linking Electronic Signatures to Identity, Training and Authorisation Matrices Context In the evolving landscape of regulatory affairs, particularly in the realms of pharmaceutical and biotechnology industries, the management of electronic records, signatures, and audit trails is paramount. With an increasing reliance on digital systems for documentation and data management, organizations must navigate the complex intersection of compliance, integrity, and security dictated by various regulations including 21 CFR Part 11 in the US and EU Annex 11 requirements. This article serves as a comprehensive guide for regulatory affairs professionals, outlining best practices,…

How to Build an Audit Trail Review Process that Adds Real Value How to Build an Audit Trail Review Process that Adds Real Value In today’s rapidly evolving regulatory landscape, particularly within the pharmaceutical and biotechnology sectors, maintaining regulatory affairs compliance is paramount. Regulatory Agencies, such as the FDA, EMA, and MHRA, have increasingly recognized the importance of digital systems, data integrity, and the requisite measures to ensure compliance with regulations such as 21 CFR Part 11 and EU Annex 11. This article will provide a detailed manual on building an effective audit trail review process that adds demonstrable value…

Electronic Records in Regulatory Submissions: Traceability and Integrity Electronic Records in Regulatory Submissions: Traceability and Integrity In today’s regulatory environment, the use of electronic records in pharmaceutical and biotechnology companies has become a standard practice. As the industry evolves, regulatory bodies such as the FDA, EMA, and MHRA impose stringent requirements on data integrity, system validation, and electronic records management. This article serves as a comprehensive guide to understanding the regulatory framework surrounding electronic records, with a specific focus on 21 CFR Part 11 compliance, EU Annex 11 requirements, and the role of GxP digital systems and validation. Regulatory Context…

Handling Hybrid Paper–Electronic Records During System Transitions Handling Hybrid Paper–Electronic Records During System Transitions In the rapidly evolving landscape of pharmaceuticals and biotechnology, organizations are increasingly required to manage both paper and electronic records. This challenge is especially significant during system transitions, where regulatory compliance becomes paramount. This article provides an in-depth regulatory explainer on the management of hybrid records, focusing on the implications of 21 CFR Part 11 compliance in the US, EU Annex 11 requirements, and best practices for ensuring data integrity. Regulatory Affairs (RA) professionals, along with CMC and Labelling teams, will find essential guidance on navigating…

Case Studies: Audit Trail and E-Record Deficiencies in FDA and EMA Inspections Case Studies: Audit Trail and E-Record Deficiencies in FDA and EMA Inspections In the pharmaceutical and biotechnology industries, maintaining regulatory compliance is crucial, especially in the face of increasing scrutiny surrounding digital systems, data integrity, and electronic record management. This article explores the regulatory framework surrounding electronic records, particularly focusing on the requirements set forth by the FDA under 21 CFR Part 11 and the EMA’s Annex 11. By examining case studies of audit trail and e-record deficiencies, it aims to provide Regulatory Affairs (RA) professionals, Quality Assurance…

Configuring Systems to Distinguish Administrative vs GxP-Relevant Audit Trails Configuring Systems to Distinguish Administrative vs GxP-Relevant Audit Trails As pharmaceutical and biotech industries increasingly integrate digital systems into their operations, ensuring compliance with relevant regulations becomes paramount. The distinction between administrative and Good Practice (GxP) relevant audit trails is crucial for meeting regulatory expectations not only within the US, UK, and EU frameworks but also for fulfilling the requirements laid out in 21 CFR Part 11 and EU Annex 11. This regulatory explainer manual addresses this topic in detail. Context The rise of digital systems in the pharmaceutical industry has…

Electronic Approvals for Change Control, CAPA and Deviations: Pitfalls and Good Practice Electronic Approvals for Change Control, CAPA and Deviations: Pitfalls and Good Practice In the landscape of pharmaceutical and biotech industries, the integration of digital systems for managing regulatory affairs is increasingly becoming the norm. Understanding 21 CFR Part 11 compliance and aligning with the EU Annex 11 requirements is crucial for ensuring data integrity and adherence to Good Automated Manufacturing Practices (GxP). This article reviews regulatory frameworks regarding electronic approvals, specifically for Change Control, Corrective and Preventative Actions (CAPA), and deviations. It will provide in-depth insights into regulatory…